Kristina Burow - Feb 13, 2025 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Director, 10%+ Owner
Signature
/s/ Michael Milligan, as Attorney-in-Fact for Kristina M. Burow
Stock symbol
NMRA
Transactions as of
Feb 13, 2025
Transactions value $
$0
Form type
4
Date filed
2/18/2025, 04:30 PM
Previous filing
Feb 3, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -46.5K -100% 0 Feb 13, 2025 Common Stock 46.5K $17.00 Direct F1, F2
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -28.6K -100% 0 Feb 13, 2025 Common Stock 28.6K $9.95 Direct F2, F3
transaction NMRA Stock Option (Right to Buy) Award +46.5K 46.5K Feb 13, 2025 Common Stock 46.5K $1.69 Direct F1, F2, F4
transaction NMRA Stock Option (Right to Buy) Award +28.6K 28.6K Feb 13, 2025 Common Stock 28.6K $1.69 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/36th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date.
F2 On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged.
F3 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024.
F4 Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.